Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 6, 1999
Grant Date -
N/A
app pub date -
Nov 17, 1995
filing date -
Nov 18, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: light chain: CDR-1: arg-ser-ser-gln-asn-ile-val-his-ser-asn-gly-asn-thr-tyr-leu-asp; CDR-2: lys-val-ser-asn-arg-phe-ser; CDR-3: phe-gln-tyr-ser-hys-val-pro-trp-thr. Heavy chain: CDR-1: asn-tyr-tyr-ile-tyr; CDR-2: gly-ile-asn-pro-thr-ser-gly-gly-ser-asn-phe-asn-glu-lys-phe-lys-thr; CDR-3: gln-gly-leu-trp-phe-asp-ser-asp-gly-arg-gly-phe-asp-phe. Use of the antibodies for therapeutical and diagnostic purposes.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully